NCT03897530

Experimental Tobacco Marketplace in Regulating Flavored Tobacco Products in Menthol Cigarette Smokers

Terminated NA Last updated 3 April 2024

What this trial tests

NA trial testing Smoking Cessation Intervention in Cigarette Smoking in 103 participants. Terminated before completion.

Timeline

30 June 2019

Primary endpoint
20 July 2023

20 July 2023

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	103
Start date	30 June 2019
Primary completion	20 July 2023
Estimated completion	20 July 2023
Sites	1 location across United States

Drugs / interventions tested

• Smoking Cessation Intervention
• Functional Assessment
• Questionnaire Administration

Conditions studied

• Cigarette Smoking — all drugs for Cigarette Smoking →

Sponsor

Roswell Park Cancer Institute

Who can join

18 and older, any sex, with Cigarette Smoking. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial uses an Experimental Tobacco Marketplace to study the purchase of tobacco products in menthol cigarette smokers. Determining the level of substitutability of both flavored and unflavored/tobacco flavored e-cigarettes when menthol cigarettes are available and unavailable can help determine if a flavor ban (of either menthol cigarettes and/or flavored e-cigarettes) will lead to smoking cessation and/or harm reduction. A greater understanding of tobacco product purchasing could help inform possible regulatory actions by the Food and Drug Administration.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Hypothetical demand for menthol and non-menthol cigarettes and substitution among people who smoke menthol cigarettes: A within subjects between group randomized controlled trial using the experimental tobacco marketplace.
   Quisenberry AJ, John L, O'Connor R, Klein EG. · · 2025 · PMID 40203666 · DOI 10.1016/j.drugalcdep.2025.112667